# An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

> **NCT07344818** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 18 (estimated)

## Conditions studied

- R/R Aggressive B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CAR-T cell therapy

## Key facts

- **NCT ID:** NCT07344818
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-07
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07344818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07344818, "An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07344818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*